Inhibitors, Agonists, Screening Libraries

www.MedChemExpress.com

Data Sheet

Product Name: Scriptaid
Cat. No.: HY-15489
CAS No.: 287383-59-9
Molecular Formula: C_{18}H_{18}N_{2}O_{4}
Molecular Weight: 326.35
Target: Autophagy; HDAC
Pathway: Autophagy; Cell Cycle/DNA Damage; Epigenetics
Solubility: DMSO: ≥ 150 mg/mL

BIOLOGICAL ACTIVITY:
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research.

IC_{50} & Target: HDAC

In Vitro: Scriptaid (1 μg/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC_{50}s of 0.5-1.0 μg/mL. Scriptaid (0.1-1.0 μg/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA, they enhance ER expression and induce a functional ER protein[^1]. Scriptaid and SAHA preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti- T. gondii compound with low cytotoxicity, and the IC_{50} is 39 nM. Scriptaid has atypical effects in T. gondii-infected HS68 cells[^2]. Scriptaid inhibits the growth of HeLa cells with IC_{50} of 2 μM at 48 h in a dose-dependent manner. Scriptaid also affects cell-cycle and apoptosis[^3].

In Vivo: Scriptaid (3.5 μg/g mouse, i.p.) clearly inhibits tumor growth in a xenograft mouse model[^1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: IC_{50} concentrations of Scriptaid are determined in MDA-MB-231, MDA-MB-435 and Hs578t cells by MTT assay. For cell growth assays, MDA-MB-231, MDA-MB-435, and Hs578t cells are plated at a cell density of 5000 cells/well in 12 well plates and treated with 1.0 μg/mL Scriptaid for up to 3 days. Cells are counted daily using a Coulter counter. Percent growth inhibition is determined by comparison of treated and untreated cells[^1]. Animal Administration: Scriptaid is dissolved in DMSO[^1]. Four to six week old athymic female nude mice are housed under laminar flow hoods in an environmentally controlled pathogen free animal facility for the duration of experiments. Mice are injected with 2×10^6 MDA-MB-231 human breast cancer cells into each flank. Tumors are allowed to grow to approximately 0.1 cm^3 in diameter before treatment. Mice are then treated with Scriptaid (3.5 μg/g mouse), TSA (0.5 μg/g mouse), or DMSO vehicle intraperitoneally for five consecutive days with 2 days rest each week for a total of 4 weeks. Individual tumor measurements are recorded from each flank weekly[^1].

References:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898    Fax: 609-228-5909    E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA